4'-fluoro-3-methyl-4-nitrobiphenyl | 1303573-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-fluoro-3-methyl-4-nitrobiphenyl
• 英文别名: 4-(4-fluorophenyl)-2-methyl-1-nitrobenzene
• CAS: 1303573-37-6
• 化学式: C₁₃H₁₀FNO₂
• 分子量: 231.226
• InChiKey: CAENDTMWWDAEFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4'-fluoro-3-methyl-4-nitrobiphenyl 在 tin(II) chloride dihdyrate 、 sodium hydride 、 苯硫酚 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 、 mineral oil 为溶剂， 反应 0.08h， 生成 methyl 5-(4-fluorophenyl)-1-hydroxy-1H-indole-2-carboxylate
  参考文献：
  名称：

  N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation

  摘要：

  Current cancer research is being increasingly focused on the study of distinctive characters of tumour metabolism, resulting in a switch from oxidative phosphorylation to glycolysis (Warburg effect). Isoform 5 of human lactate dehydrogenase (hLDH5), which catalyzes the final step in the glycolytic cascade (pyruvate to lactate), constitutes a relatively new and untapped anti-cancer target. In this study, careful design and synthesis of a selected series of aryl-substituted N-hydroxyindole-2-carboxylates (NHIs) has led to several hLDH5-inhibitors, showing "first-in-class" potency and isoform selectivity. Enzyme kinetics studies indicated that these inhibitors exhibit a competitive mode of inhibition. Some representative examples were tested against two human pancreatic carcinoma cell lines, and displayed a good antiproliferative activity, which was even more evident under hypoxic conditions. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.08.046
• 作为产物：
  描述：

  5-氯-2-硝基甲苯 、 4-氟苯硼酸 在 四丁基溴化铵 、 palladium diacetate 、 sodium carbonate 作用下， 以 水 为溶剂， 反应 0.08h， 以86%的产率得到4'-fluoro-3-methyl-4-nitrobiphenyl
  参考文献：
  名称：

  N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation

  摘要：

  Current cancer research is being increasingly focused on the study of distinctive characters of tumour metabolism, resulting in a switch from oxidative phosphorylation to glycolysis (Warburg effect). Isoform 5 of human lactate dehydrogenase (hLDH5), which catalyzes the final step in the glycolytic cascade (pyruvate to lactate), constitutes a relatively new and untapped anti-cancer target. In this study, careful design and synthesis of a selected series of aryl-substituted N-hydroxyindole-2-carboxylates (NHIs) has led to several hLDH5-inhibitors, showing "first-in-class" potency and isoform selectivity. Enzyme kinetics studies indicated that these inhibitors exhibit a competitive mode of inhibition. Some representative examples were tested against two human pancreatic carcinoma cell lines, and displayed a good antiproliferative activity, which was even more evident under hypoxic conditions. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.08.046

文献信息

• Phenyl benzoic acid compounds
  申请人：Merck & Co., Inc.

  公开号：US04044049A1

  公开（公告）日：1977-08-23

  The invention relates to substituted 5-(phenyl)benzoic acid esters and non-toxic pharmaceutically accepted salts thereof and processes for their preparation. The substituted 5-(phenyl)benozic acids are useful as anti-inflammatory compounds. Also included are method of treating inflammation claims by administering these particular compounds to patients.

  本发明涉及取代的5-(苯基)苯甲酸酯及其无毒药学可接受盐和其制备方法。这些取代的5-(苯基)苯甲酸可用作抗炎化合物。本发明还包括通过向患者投与这些特定化合物来治疗炎症的方法声明。
• US4044049A
  申请人：——

  公开号：US4044049A

  公开（公告）日：1977-08-23